Viatris (VTRS)
(Delayed Data from NSDQ)
$11.39 USD
+0.01 (0.09%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $11.40 +0.01 (0.09%) 7:58 PM ET
4-Sell of 5 4
A Value F Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.39 USD
+0.01 (0.09%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $11.40 +0.01 (0.09%) 7:58 PM ET
4-Sell of 5 4
A Value F Growth D Momentum C VGM
Zacks News
Why Viatris (VTRS) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Viatris (VTRS) to Divest Some More Businesses, Shares Gain
by Zacks Equity Research
Viatris (VTRS) enters into agreements to divest its remaining businesses previously planned for 2023. Its shareholders are upbeat about the same.
Viatris (VTRS) Gets FDA Nod for Pupil Dilation Reversal Agent
by Zacks Equity Research
Viatris (VTRS) and partner Ocuphire Pharma receive FDA approval for Ryzumvi to treat pharmacologically-induced mydriasis of the pupils.
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
Why Is Viatris (VTRS) Down 4.8% Since Last Earnings Report?
by Zacks Equity Research
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Viatris (VTRS) Gets Tentative Approval for HIV Regimen for Kids
by Zacks Equity Research
Viatris (VTRS) obtains tentative approval from the FDA for a pediatric formulation of abacavir/dolutegravir/lamivudine, a once-daily treatment for children living with HIV.
Viatris (VTRS)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Theravance's (TBPH) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Thervance's (TBPH) second-quarter 2023 loss is narrower than expected. Revenues rise year over year.
Company News for Aug 8, 2023
by Zacks Equity Research
Companies in The News Are: KKR,SAGE,VTRS,FRPT
Viatris (VTRS) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Viatris (VTRS) Q2 Earnings Beat, Generics Business Grows
by Zacks Equity Research
Viatris (VTRS) second-quarter earnings and sales beat estimates. The company reiterates its annual guidance.
Viatris (VTRS) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of 5.63% and 0.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Viatris' (VTRS) Q2 results are likely to be impacted by foreign exchange rates. Nevertheless, momentum in the branded business is likely to have continued.
Viatris (VTRS) Flat As Market Gains: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $9.85, making no change from the previous trading session.
Why Is Viatris (VTRS) Down 2.4% Since Last Earnings Report?
by Zacks Equity Research
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Theravance's (TBPH) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Thervance's (TBPH) first-quarter 2023 loss wider than expected. Revenues decline year over year and also miss estimates.
Viatris (VTRS) Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) beats on Q1 earnings but misses sales. The company is now looking to reshape its business after selling its biosimilars portfolio.
Viatris (VTRS) Tops Q1 Earnings Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of 13.04% and 1.75%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Viatris' (VTRS) Q1 results are likely to be impacted by competitive pressure. With the Biocon deal closed, investors await its impact on first-quarter sales.
Bausch + Lomb (BLCO) Q1 Earnings Lag Estimates
by Zacks Equity Research
Bausch + Lomb (BLCO) delivered earnings and revenue surprises of -28.57% and 3.98%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $9.36, moving +0.32% from the previous trading session.
Icon PLC (ICLR) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of -2.68% and 0.35%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
The Zacks Analyst Blog Highlights Humana, Viatris, agilon health and Cano Health
by Zacks Equity Research
Humana, Viatris, agilon health and Cano Health are included in this Analyst Blog.